Tech Center 1600 • Art Units: 1631 1633
This examiner grants 69% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17917315 | METHODS OF GENERATING PLURIPOTENT STEM CELL-DERIVED VASCULAR SMOOTH MUSCLE CELLS, USES, AND COMPOSITION RELATED THERETO | Non-Final OA | EMORY UNIVERSITY |
| 17776622 | HEMATOPOIETIC PRECURSOR CELL PRODUCTION | Final Rejection | AMGEN INC. |
| 17707215 | MEDIUM FOR CULTURING HEPATOCYTE, METHOD OF PRODUCING HEPATOCYTE, AND HEPATOCYTE | Non-Final OA | FUJIFILM Corporation |
| 18314671 | CELL SPECIFIC GENE THERAPY DELIVERY COMPOSITIONS AND METHODS FOR TREATING HEARING LOSS | Non-Final OA | Akouos, Inc. |
| 17734550 | CELL CULTURE FOR TREATING DISEASE IN THE LOWER LIMBS | Final Rejection | TERUMO KABUSHIKI KAISHA |
| 18379740 | PROLYL HYDROXYLASE DOMAIN INHIBITOR TREATMENT TO IMPROVE SURVIVABILITY OF HEMORRHAGIC SHOCK | Non-Final OA | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY |
| 18285970 | ORAL VACCINE COMPOSITION | Non-Final OA | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION |
| 18265544 | COMPOUNDS AND METHODS TO TREAT CYSTIC FIBROSIS | Non-Final OA | City of Hope |
| 18163816 | RECOMBINANT CARDIOMYOCYTES AND CARDIOMYOCYTE CELL LINES EXPRESSING HERG | Non-Final OA | The Governors of the University of Alberta |
| 18361712 | GENE MODIFIED IPSC DERIVED CELLULAR COMPOSITIONS FOR REGENERATION AND IMMUNE MODULATION | Non-Final OA | Therapeutic Solutions International, Inc. |
| 18561862 | METHODS FOR STORING MRNA COMPOSITIONS | Non-Final OA | eTheRNA immunotherapies NV |
| 17998587 | VIRAL VECTORS EXPRESSING THERAPEUTIC PROTEINS SPECIFICALLY IN MYELOID CELLS AND MICROGLIA | Non-Final OA | UNIVERSITÄT ZÜRICH |
| 18227775 | ON DEMAND EXPRESSION OF EXOGENOUS FACTORS IN LYMPHOCYTES | Non-Final OA | American Gene Technologies International Inc. |
| 18551476 | METHODS FOR MAINTAINING LONG-TERM PLATELET VIABILITY AND ACTIVATABILITY | Non-Final OA | RETHAM TECHNOLOGIES, LLC |
| 18273845 | MODULATION OF AAV-BASED GENE EXPRESSION | Non-Final OA | Prevail Therapeutics, Inc. |
| 17911601 | COMPOSITIONS AND METHODS FOR REDUCING REVERSE PACKAGING OF CAP AND REP SEQUENCES IN RECOMBINANT AAV | Non-Final OA | Ultragenyx Pharmaceutical Inc. |
| 18190879 | DEVICES AND METHODS FOR ISOLATING TUMOR INFILTRATING LYMPHOCYTES AND USES THEREOF | Non-Final OA | INSTIL BIO (UK) LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy